Report Adverse Event or Product Quality Complaint    US Site     Global Site

AZmedical Information Logo
  • Prescribing Information
  • Therapy areas
    • All Therapeutic Areas
    • Cardiovascular, Renal and Metabolism
    • Immunology
    • Infection
    • Oncology
    • Rare Disease (Alexion)
    • Respiratory
  • Disease Education
  • Resources
    • Congress Library
    • Clinical Trials
    • Continuing Education
    • Patient Support
    • Pipeline
    • Oncology Pipeline Tool
  • Connect
    • Connect with an MSL
    • Connect with an MSL
    • Submit an Medical Information Request
    • Give Feedback

Search Medical Information

Login

Request a field medical follow-up

  • Home
  • Congress Library
  • AANEM 2026

  American Association of Neuromuscular & Electrodiagnostic Medicine (AANEM 2026 including MGFA) Annual Meeting

 September 29 - October 2, 2026

  1. All
  2. gMG

PDF

Analysis of associations between myasthenia gravis activities of daily living (MG-ADL) total scores and myasthenic exacerbations and crises risk using a US open claims database and chart notes

PDF

Clinical deterioration, rescue therapy, and hospitalization among patients with generalized myasthenia gravis (gMG): results from the PREVAIL trial of gefurulimab

PDF

Comparing longitudinal treatment-related adverse risks of infection in generalized myasthenia gravis

PDF

Complement c5 inhibition preserves the neuromuscular junction in myasthenia gravis: an integrated morphology and in vivo nerve evoked muscle function biomarker platform in rodent models

PDF

Corticosteroid usage and comorbidities among patients with generalized myasthenia gravis in the United States

PDF

Effect of subcutaneous self-administered gefurulimab on ocular muscle function in myasthenia gravis in the PREVAIL trial

PDF

Health-related quality of life in patients with generalized myasthenia gravis receiving gefurulimab in the PREVAIL trial

PDF

Long-term effectiveness, safety, and quality of life (QOL) of ravulizumab in generalized myasthenia gravis (gMG): an analysis of the global MG spotlight registry

PDF

Long-term efficacy and safety of gefurulimab in adults with generalized myasthenia gravis (gMG): results from the open-label extension (OLE) of the PREVAIL trial

HTML

ME&MGTM digital biomarker scores reflect MGFA severity classification

PDF

Reductions in clinical deteriorations and healthcare resource utilization after switch from efgartigimod to ravulizumab in patients with gMG in the US

HTML

The DOMYA study to validate ME&MGTM digital biomarkers for remote monitoring of generalized myasthenia gravis

PDF

The phase 4 OCTAGON study investigating oral corticosteroid tapering in adult patients with generalized myasthenia gravis treated with ravulizumab: trial in progress

PDF

Time to response and minimal symptom expression with gefurulimab in generalized myasthenia gravis (gMG): 52-week results from the phase 3 PREVAIL trial

PDF

Analysis of associations between myasthenia gravis activities of daily living (MG-ADL) total scores and myasthenic exacerbations and crises risk using a US open claims database and chart notes

PDF

Clinical deterioration, rescue therapy, and hospitalization among patients with generalized myasthenia gravis (gMG): results from the PREVAIL trial of gefurulimab

PDF

Comparing longitudinal treatment-related adverse risks of infection in generalized myasthenia gravis

PDF

Complement c5 inhibition preserves the neuromuscular junction in myasthenia gravis: an integrated morphology and in vivo nerve evoked muscle function biomarker platform in rodent models

PDF

Corticosteroid usage and comorbidities among patients with generalized myasthenia gravis in the United States

PDF

Effect of subcutaneous self-administered gefurulimab on ocular muscle function in myasthenia gravis in the PREVAIL trial

PDF

Health-related quality of life in patients with generalized myasthenia gravis receiving gefurulimab in the PREVAIL trial

PDF

Long-term effectiveness, safety, and quality of life (QOL) of ravulizumab in generalized myasthenia gravis (gMG): an analysis of the global MG spotlight registry

PDF

Long-term efficacy and safety of gefurulimab in adults with generalized myasthenia gravis (gMG): results from the open-label extension (OLE) of the PREVAIL trial

HTML

ME&MGTM digital biomarker scores reflect MGFA severity classification

PDF

Reductions in clinical deteriorations and healthcare resource utilization after switch from efgartigimod to ravulizumab in patients with gMG in the US

HTML

The DOMYA study to validate ME&MGTM digital biomarkers for remote monitoring of generalized myasthenia gravis

PDF

The phase 4 OCTAGON study investigating oral corticosteroid tapering in adult patients with generalized myasthenia gravis treated with ravulizumab: trial in progress

PDF

Time to response and minimal symptom expression with gefurulimab in generalized myasthenia gravis (gMG): 52-week results from the phase 3 PREVAIL trial

Disclaimer

Some content may have changed since publication. Some links may require registration/login to access the content. Any attached publications and/or any tables or figures derived from the publications are copyright-protected works. AstraZeneca has obtained permission from the copyright owner to use this work on this site. You may not reproduce, prepare derivative works from, display or distribute this work unless you obtain the permission of the copyright owner, or as otherwise might be permitted by law.

Connessiallasalute.it

This site is intended for healthcare professionals practicing in the US.
©2026 AstraZeneca. All rights reserved.

US-107328
Last Updated 5/26

Contact Us

About Us

AstraZeneca-US.com

Other Countries

Grant Opportunities  

Survey Feedback

Your Privacy Choice

Consumer Health Data
Privacy Notice

Privacy Notice | Legal Notice | Cookie Preferences

Welcome to AstraZeneca Medical Information

The information provided on this site is intended for use by healthcare professionals practicing in the US. The dissemination of this information may be subject to different medical and regulatory requirements in other countries.

 

This web site is intended to help healthcare professionals practicing in the US and AstraZeneca authorized persons find scientifically balanced, evidence-based information about AstraZeneca drugs, submit a question, ask for field medical follow-up, and explore links to professional and patient support resources.

 

Are you a healthcare professional practicing in the United States?

I am an AstraZeneca authorized person   What is an AstraZeneca authorized person?
This website is only intended for healthcare professionals practicing in the United States and authorized AstraZeneca personnel. AstraZeneca US Headquarters personnel and US Field Medical personnel are authorized to browse and search the database for their own background knowledge and insight. US Field Sales personnel should not access or browse this site. None of the content of this site should be directly linked or distributed without approval.
I am not a healthcare professional practicing in the United States